Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates

dc.contributor.authorKarakus, Gozde Sir
dc.contributor.authorTastan, Cihan
dc.contributor.authorKancagi, Derya Dilek
dc.contributor.authorYurtsever, Bulut
dc.contributor.authorTumentemur, Gamze
dc.contributor.authorDemir, Sevda
dc.contributor.authorTuran, Raife Dilek
dc.contributor.authorAbanuz, Selen
dc.contributor.authorCakirsoy, Didem
dc.contributor.authorSeyis, Utku
dc.contributor.authorOzer, Samed
dc.contributor.authorElibol, Omer
dc.contributor.authorElek, Muhammer
dc.contributor.authorErtop, Gurcan
dc.contributor.authorArbale, Serap
dc.contributor.authorElmas, Merve Acikel
dc.contributor.authorHermsinlioglu, Canso
dc.contributor.authorKocagoz, Ayse Sesin
dc.contributor.authorNg, Ozden Hatirnaz
dc.contributor.authorAkyoney, Sezer
dc.contributor.authorSahin, Ilayda
dc.contributor.authorOzbek, Ugur
dc.contributor.authorTelci, Dilek
dc.contributor.authorSahin, Fikrettin
dc.contributor.authorYalcin, Koray
dc.contributor.authorRatip, Siret
dc.contributor.authorOvali, Ercument
dc.date.accessioned2023-02-21T12:38:00Z
dc.date.available2023-02-21T12:38:00Z
dc.date.issued2021-01-01
dc.description.abstractCOVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1(V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice.
dc.description.issue1
dc.description.issueMAR 11
dc.description.volume11
dc.identifier.doi10.1038/s41598-021-83930-6
dc.identifier.urihttps://hdl.handle.net/11443/2325
dc.identifier.urihttp://dx.doi.org/10.1038/s41598-021-83930-6
dc.identifier.wosWOS:000629623300078
dc.publisherNATURE RESEARCH
dc.relation.ispartofSCIENTIFIC REPORTS
dc.titlePreclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
s41598-021-83930-6 (1).pdf
Size:
3.61 MB
Format:
Adobe Portable Document Format

Collections